693 related articles for article (PubMed ID: 33188997)
1. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
2. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Wilson WH; Wright GW; Huang DW; Hodkinson B; Balasubramanian S; Fan Y; Vermeulen J; Shreeve M; Staudt LM
Cancer Cell; 2021 Dec; 39(12):1643-1653.e3. PubMed ID: 34739844
[TBL] [Abstract][Full Text] [Related]
3. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
4. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
5. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
Johnson PWM; Balasubramanian S; Hodkinson B; Shreeve SM; Sun S; Srinivasan S; Steele AJ; Vermeulen J; Sehn LH; Wilson WH
Blood Adv; 2023 May; 7(10):2008-2017. PubMed ID: 36696540
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
8. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W
Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
11. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
[TBL] [Abstract][Full Text] [Related]
12. ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
Davies A; Barrans S; Burton C; Mercer K; Caddy J; Chinnery F; Day L; Fernando D; Ardeshna K; Collins G; Radford J; Rule S; McMillan A; Johnson P; Griffiths G
F1000Res; 2020; 9():941. PubMed ID: 33093947
[No Abstract] [Full Text] [Related]
13. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
[TBL] [Abstract][Full Text] [Related]
15. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
16. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
18. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
19. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma.
Park S; Jo JC; Do YR; Yang DH; Lim SN; Lee WS; Kim WS; Lee HS; Hong DS; Kim HJ; Shin HJ
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):149-156. PubMed ID: 30581162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
